Last reviewed · How we verify
VB10.NEO
At a glance
| Generic name | VB10.NEO |
|---|---|
| Also known as | Atezolizumab, Tecentriq |
| Sponsor | Nykode Therapeutics ASA |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of VB10.NEO in Combination With Atezolizumab in Solid Tumors (PHASE1)
- A Study to Evaluate Safety and Efficacy of Multiple Dosing With VB10.NEO and Bempegaldesleukin (NKTR-214) Immunotherapy in Patients With Locally Advanced or Metastatic Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VB10.NEO CI brief — competitive landscape report
- VB10.NEO updates RSS · CI watch RSS
- Nykode Therapeutics ASA portfolio CI